Tigris Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.tigrispharma.com
Clinical Trials
4
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)Study of AFP464 +/- Faslodex in ER + Breast Cancer
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2012-01-09
- Lead Sponsor
- Tigris Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT01233947
- Locations
- 🇺🇸
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Neoplasm
- Interventions
- Drug: Aminoflavone Prodrug
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- Tigris Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT01015521
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
Phase 2
Completed
- Conditions
- Cervical Intraepithelial NeoplasiaUterine Cervical Dysplasia
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Tigris Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT00596258
- Locations
- 🇺🇸
Visions Clinical Research-Tucson, Tucson, Arizona, United States
🇺🇸Robin Black OGNP, Costa Mesa, California, United States
🇺🇸Visions Clinical Research, Boynton Beach, Florida, United States
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
Phase 2
Completed
- Conditions
- Cervical Intraepithelial NeoplasiaUterine Cervical Dysplasia
- Interventions
- Drug: placebo
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2010-10-11
- Lead Sponsor
- Tigris Pharmaceuticals
- Target Recruit Count
- 147
- Registration Number
- NCT00285207
- Locations
- 🇺🇸
University of Alabama Highlands, Dept. of OB/GYN, Birmingham, Alabama, United States
🇺🇸Hope Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Visions Clinical Research-Tucson, Tucson, Arizona, United States
News
No news found